Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...

(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...

Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...